Lawsuits allege that long-term use of the Depo-Provera birth control shot is associated with an increased risk of meningioma — a tumor that forms in the tissue surrounding the brain and spinal cord.
Depo-Provera (medroxyprogesterone acetate) is a hormone-based injectable contraceptive administered roughly every three months. It has been on the market for decades and is used by millions of women in the United States.
In 2024, a large study published in the British Medical Journal reported that prolonged use of medroxyprogesterone acetate was associated with a substantially increased risk of intracranial meningioma. Following the study, women across the country began filing lawsuits alleging that the manufacturer knew or should have known about the risk and failed to adequately warn patients and physicians.
The litigation has been consolidated into a federal multidistrict litigation (MDL) in the Northern District of Florida, where cases are coordinated for pretrial proceedings.
Cases are actively being filed and consolidated in a federal MDL. The litigation is in early stages — no global settlement has been announced, and qualifying criteria continue to evolve.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Depo Provera campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Depo-Provera. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.